Back to results
US 8,222,036 B2Granted
Oncolytic viruses as phenotyping agents for neoplasms
AssigneeOncoltyics Biotech Inc.
InventorsBradley G. Thompson, Matthew C. Coffey
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOncoltyics Biotech Inc.
InventorsBradley G. Thompson, Matthew C. Coffey
Estimating the term…
The present invention provides a method of diagnosing neoplasms having a particular phenotype by using oncolytic viruses that selectively replicate in neoplasms having the particular phenotype. For example, reovirus does not replicate in normal cells. However, reovirus selectively replicate in cells with an activated ras pathway, which leads to death of these cells. Therefore, a cell which becomes neoplastic due to, at least in part, elevated ras pathway activities can be diagnosed by its susceptibility to reovirus replication. This invention can further be applied, using other oncolytic viruses, to the diagnosis and/or treatment of other tumors, such as interferon-sensitive tumors, p53-deficient tumors and Rb-deficient tumors. Kits useful in the diagnosis or treatment disclosed herein are also provided.
A kit comprising at least two different oncolytic viruses and a means for detecting replications of the oncolytic viruses, wherein each oncolytic virus selectively replicates in one or more of ras-activated neoplastic cells, interferon resistant neoplastic cells, p53-deficient neoplastic cells or Rb-deficient neoplastic cells.
A kit comprising at least two different oncolytic viruses and a means for detecting replications of the oncolytic viruses, wherein each oncolytic virus has a different phenotype specificity selected from the group consisting of ras pathway activation, interferon-resistance, p53 deficiency and Rb-deficiency.
Dependencies are inferred from the claim text.